TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

[1]  M. Kwiatkowski,et al.  TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone , 2019, Nature Communications.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  C. Wilson,et al.  Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. , 2018, European journal of cancer.

[4]  Gehad El Ashal,et al.  Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials , 2018, Supportive Care in Cancer.

[5]  T. Fehm,et al.  German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Chuang Chen,et al.  Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study , 2017, Oncotarget.

[7]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[8]  He Weiwei,et al.  TGIF1 promoted the growth and migration of cancer cells in nonsmall cell lung cancer , 2015, Tumor Biology.

[9]  Bing Xu,et al.  Elevated expression of TGIF is involved in lung carcinogenesis , 2015, Tumor Biology.

[10]  R. Baron,et al.  TGIF governs a feed-forward network that empowers Wnt signaling to drive mammary tumorigenesis. , 2015, Cancer cell.

[11]  A. Schneeweiss,et al.  German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[13]  M. Clemons,et al.  Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated? , 2012, Breast Cancer Research and Treatment.

[14]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[15]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[16]  D. Xiao,et al.  Effects of transforming growth interacting factor on biological behaviors of gastric carcinoma cells. , 2005, World journal of gastroenterology.

[17]  J. Massagué,et al.  Multiple Modes of Repression by the Smad Transcriptional Corepressor TGIF* , 1999, The Journal of Biological Chemistry.

[18]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[19]  T R Bürglin,et al.  Analysis of TALE superclass homeobox genes (MEIS, PBC, KNOX, Iroquois, TGIF) reveals a novel domain conserved between plants and animals. , 1997, Nucleic acids research.

[20]  E. Bertolino,et al.  A Novel Homeobox Protein Which Recognizes a TGT Core and Functionally Interferes with a Retinoid-responsive Motif (*) , 1995, The Journal of Biological Chemistry.

[21]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[22]  M. Stockler,et al.  Bisphosphonates and other bone agents for breast cancer. , 2012, The Cochrane database of systematic reviews.

[23]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[25]  J. Massagué,et al.  Smad transcriptional corepressors in TGF beta family signaling. , 2001, Current topics in microbiology and immunology.

[26]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .